These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 35867811)

  • 1. Interferon resistance of emerging SARS-CoV-2 variants.
    Guo K; Barrett BS; Morrison JH; Mickens KL; Vladar EK; Hasenkrug KJ; Poeschla EM; Santiago ML
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2203760119. PubMed ID: 35867811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon Resistance of Emerging SARS-CoV-2 Variants.
    Guo K; Barrett BS; Mickens KL; Vladar EK; Morrison JH; Hasenkrug KJ; Poeschla EM; Santiago ML
    bioRxiv; 2021 Dec; ():. PubMed ID: 33758840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging mutation patterns in SARS-CoV-2 variants.
    Ostrov DA; Knox GW
    Biochem Biophys Res Commun; 2022 Jan; 586():87-92. PubMed ID: 34837837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue.
    Shi G; Li T; Lai KK; Johnson RF; Yewdell JW; Compton AA
    Nat Commun; 2024 Jan; 15(1):889. PubMed ID: 38291024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada.
    Jacob RA; Zhang A; Ajoge HO; D'Agostino MR; Nirmalarajah K; Shigayeva A; Demian WL; Baker SJC; Derakhshani H; Rossi L; Nasir JA; Panousis EM; Draia AN; Vermeiren C; Gilchrist J; Smieja N; Bulir D; Smieja M; Surette MG; McArthur AG; McGeer AJ; Mubareka S; Banerjee A; Miller MS; Mossman K
    Emerg Infect Dis; 2023 Jul; 29(7):1386-1396. PubMed ID: 37308158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omicron: a drug developer's perspective.
    Fang FF; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):208-211. PubMed ID: 34951568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
    Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
    J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effective Inhibitory Concentration of Interferon-β Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants.
    Singh J; Anantharaj A; Kumar P; Pandey R; Pandey AK; Medigeshi GR
    J Interferon Cytokine Res; 2024 Jul; 44(7):325-333. PubMed ID: 38557204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
    Bui NN; Lin YT; Huang SH; Lin CW
    Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics.
    Chauhan D; Chakravarty N; Jeyachandran AV; Jayakarunakaran A; Sinha S; Mishra R; Arumugaswami V; Ramaiah A
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.